Bristol Myers Squibb
Untracked preview. This is not a tracked Signal Bureau entity — the page is generated on request from live coverage search, is not indexed, and carries no editorial curation. Tracked entities live on the Wire.
U.S. pharma major with a broad oncology and immunology portfolio.
If Bristol Myers Squibb is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea · Fierce Biotech · 2026-08-03
- STAT+: Pharmalittle: We’re reading about a Medicare pilot and orphan drugs, Pfizer cutbacks, and more · STAT News — All Content · 2026-08-06
- Higher Blood-to-Tissue Tumor Mutational Burden Ratio Is Associated With Poorer Overall Survival in Advanced Non-Small Cell Lung Cancer · medRxiv Oncology · 2026-08-06
- Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui · Fierce Biotech · 2026-08-06
- Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle · Fierce Pharma · 2026-08-07 · usually covers FDA Decisions
- How can I safely remove the cells from this pack? · Reddit r/batteries · 2026-08-07 · usually covers Battery Storage
What the reporting says
Across 47 tracked stories from 14 outlets, reporting on Bristol Myers Squibb most often describes acquisition (8), IPOs or listings (4), launches or releases (3), regulatory approvals (2), public statements (1).
It shows up alongside Astrazeneca (26 — acquisition ×3), Pfizer (16), Merck (13), Novartis (10), Eli Lilly (8), Immunotherapy (14), China (10).
Two steps out: AI (through Immunotherapy, 14 shared stories on the weaker link); Colorectal Cancer (through Immunotherapy, 14 shared stories on the weaker link); ctDNA (through Immunotherapy, 14 shared stories on the weaker link); FDA (through Pfizer, 14 shared stories on the weaker link).
Tracked since Jul 6, with coverage on 17 separate days — concentrated in Biotech Pharma and Preprint.